| 中药抑制非小细胞肺癌PI3K/Akt/mTOR信号通路克服EGFR-TKIs获得性耐药研究进展 |
| |
| 引用本文： | 蔡鹏涛,吴志强,郭会,舒琦瑾. 中药抑制非小细胞肺癌PI3K/Akt/mTOR信号通路克服EGFR-TKIs获得性耐药研究进展[J]. 中草药, 2015, 46(12): 1849-1852 |
| |
| 作者姓名： | 蔡鹏涛 吴志强 郭会 舒琦瑾 |
| |
| 作者单位： | 浙江中医药大学, 浙江 杭州 310053;浙江中医药大学, 浙江 杭州 310053;浙江中医药大学, 浙江 杭州 310053;浙江中医药大学附属第一医院 肿瘤科, 浙江 杭州 310006 |
| |
| 基金项目： | 国家自然科学基金面上项目(81173247) |
| |
| 摘 要： | 随着对肺癌发病机制及其生物学特性研究的不断深入,分子靶向治疗尤其是表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKIs)在非小细胞肺癌治疗方面取得了突破性进展,然而经过6~12个月的治疗后,大部分患者会对EGFR-TKIs产生获得性耐药。PI3K/Akt/mTOR信号通路在非小细胞肺癌的发生发展中具有重要的作用,该通路在肿瘤治疗方面已经有了比较广泛的研究。中药在对抗EGFR-TKIs耐药方面有很大的前景。就近年来中药通过抑制非小细胞肺癌PI3K/Akt/mTOR信号通路来克服EGFR-TKIs获得性耐药的研究进展进行综述。
|
| 关 键 词： | 表皮生长因子受体-酪氨酸激酶抑制剂 获得性耐药 PI3K/Akt/mTOR信号通路 非小细胞肺癌 中药 |
| 收稿时间： | 2014-11-04 |
Research progress on Chinese materia medica in overcoming EGFR-TKIs acquired drugs resistance through PI3K/Akt/mTOR pathway |
| |
| CAI Peng-tao,WU Zhi-qiang,GUO Hui and SHU Qi-jin. Research progress on Chinese materia medica in overcoming EGFR-TKIs acquired drugs resistance through PI3K/Akt/mTOR pathway[J]. Chinese Traditional and Herbal Drugs, 2015, 46(12): 1849-1852 |
| |
| Authors: | CAI Peng-tao WU Zhi-qiang GUO Hui SHU Qi-jin |
| |
| Affiliation: | Zhejiang Chinese Medical University, Hangzhou 310053, China;Zhejiang Chinese Medical University, Hangzhou 310053, China;Zhejiang Chinese Medical University, Hangzhou 310053, China;Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, China |
| |
| Abstract: | With in-depth study of the pathogenesis of lung cancer and its biological behaviour, molecular targeted therapy, especially the epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) made a breakthrough in non-small cell lung cancer treatment. However, the majority of patients can produce the resistance to EGFR-TKIs after 6 to 12 months treatment, which called acquired drug resistance. PI3K/Akt/mTOR pathway plays an important role in the development of non-small cell lung cancer, this pathway in cancer treatment has been widely studied. Chinese materia medica (CMM) in overcoming EGFR-TKIs resistance has a bright future, In this review, we show the developments on CMM in overcoming EGFR-TKIs acquired drugs resistance through PI3K/Akt/mTOR pathway. |
| |
| Keywords: | epidermal growth factor receptor tyrosine kinase inhibitors acquired drugs resistance PI3K/Akt/mTOR pathway non- small cell lung cancer Chinese materia medica |
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《中草药》浏览原始摘要信息 |
|
点击此处可从《中草药》下载全文 |
|
